Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-12-17-Speech-3-102"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-12-17"^^xsd:date2
dcterms:Is Part Of	lp_eu:Vote2
dcterms:Language	"el"^^xsd:language2
lpv:document identification number	"en.20031217.4.3-102"2
lpv:hasSubsequent	lp_eu:2003-12-17-Speech-3-1032
lpv:speaker	lp:Alexandros Alavanos2
lpv:spokenAs	member; Committee on Culture, Youth, Education, the Media and Sport (2002-01-17--2004-04-14)3 member; EUL/NGL (1999-07-20--2004-04-14)3 member; Delegation for relations with the countries of south-east Europe (2002-02-07--2004-04-14)3 unknown; Synaspismos tis Aristeras kai tis Proodou (1999-07-20--2004-04-14)3 substitute; Committee on Foreign Affairs, Human Rights, Common Security and Defence Policy (2002-01-17--2004-04-14)3
lpv:translated text	". The recommendation on a code for medicinal products is extremely important in an area to which European citizens are highly sensitive but which is ruled by the profiteering interests of the large companies. On this basis, I voted in favour of all the amendments which aim to: supervise the market independently of the pharmaceutical industry; protect the public from medicinal products which have expired; reduce the period of commercial secrecy demanded by the large pharmaceutical companies, the result of which is to prevent cheaper drugs from being marketed; limit advertising of medicinal products; set up databases independently of the pharmaceutical companies."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph